СЕЛЕКТИВНЫЙ АНТАГОНИСТ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ ЭПЛЕРЕНОН В КАРДИОЛОГИЧЕСКОЙ ПРАКТИКЕ
https://doi.org/10.20996/1819-6446-2015-11-2-177-181
Аннотация
Рассматривается роль альдостерона в патофизиологических процессах. Анализируются эффекты селективного антагониста минералокортикоидных рецепторов эпле-ренона. Обсуждаются преимущества эплеренона в сравнении со спиронолактоном.
Об авторах
Б. Б. Гегенава
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
д.м.н., профессор, зам. директора по научной и инновационной деятельности Научно-образовательного клинического центра инновационной терапии, профессор кафедры пропедевтики внутренних болезней, руководитель отделения кардиологии Университетской клинической больницы №2
119991, Москва, ул. Трубецкая, 8, стр. 2
О. М. Драпкина
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
врач-терапевт лечебно-диагностического отделения №4 Университетской клинической больницы №2, аспирант кафедры пропедевтики внутренних болезней
119991, Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
2. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-77.
4. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
5. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009; 21: 1658-65.
6. Laragh JH. Aldosterone in fluid and electrolyte disorders: Hyper and hypoaldosteronism. J Clin Dis 1960;11:292-318.
7. Laragh JH. Cirrhosis for renal-adrenal interaction from studies in hypertension and in failure: Vasopressin, aldosterone, and angiotensin II: further evidence hormones and the pathogenesis of congestive heart. Circulation 1962;25:1015-23.
8. O’Neil RG, Hayhurst RA. Sodium-dependent modulation of the renal Na-K-ATPase: Influence of mineralocorticoids on the cortical collecting duct. J Membr Biol 1985;8:169-79.
9. Brilla CG, Weber KT. Mineral ocorticoid excess, dietarysodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.
10. Brilla CG, Matsubara LS, Weber KT. Anti-aldosteronetreatment and the prevention of myocardial fibrosis in primary and secondary ldosteronism. J Mol Cell Cardiol 1993;25:563-75.
11. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995;26(6 Pt 1):971-8.
12. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578-83.
13. Harda E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.
14. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
15. Carey RM. Aldosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2010;17: 194-8.
16. Chai W, Garrelds IM, de Vries R, et al. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005;46:701-6.
17. Romagni P, Rossi F, Guerrini L, et al. Aldosterone induces contraction of the resistance arteries in man. Athero sclerosis 2003;166:345-9.
18. Fujita M, Minamino T, Asanuma H, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005;46:113-7.
19. Struthers A, Krum H, Williams GH. A comparison of the aldosteroneblocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8.
20. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
21. Tait JF, Little B, Tait SAS, et al. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 1965;25:219-28.
22. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15(1):79-87.
23. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364:11-21.
24. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53:286-90.
25. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
26. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.
27. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol 2002;34:1577-84.
28. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45.
29. Fung JW, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406-10.
30. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64.
31. Boccanelli A, Mureddu GF, Cacciatore G, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009;11:68-76.
32. Cohn JN, Anand IS, Latini R, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003;108:1306-9.
33. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-7.
34. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753-5.
35. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.
36. I Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-9.
37. Swedberg K1, Zannad F, McMurray JJ, et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59(18): 1598-603.
38. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
39. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
40. Neuberger HR, Mewis C, van Veldhuisen DJ, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007;28: 2568-77.
41. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45: 1832-9.
42. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.
43. Yusuf S, Healey JS, Pogue J, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-38
44. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28:457-62.
45. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007:CD005049.
46. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
47. Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005;26:2193-9.
48. Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010;159:1584-94.
49. Remuzzi G, Benigi A and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-96.
50. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-85.
51. Parving HH, Person F, Lewis JB, et al. AVOID Study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46.
52. Tsuboi N, Kawamura T, Okonogi H, et al. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst 2012;13(1):113-7.
53. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-9.
54. Bomback AS, Kshirsagar AV, Amamoo A, et al. Change in proteinuria after adding aldosterone blocker to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
55. Bianchi S, Bigazzi R, Campese VM, et al. Antagonist of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.
56. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-9.
57. Chrysostomou A, Pedagogos E, MacGregor L, et al. Doubleblind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-62.
58. Tylicki L, Rutkowski P, Renke M, et al. Triple blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-93.
59. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-51.
60. Ahn JH, Hong HC, Cho MJ, et al. Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats. Diabetes & Metabolism Journal 2012;36(2):128-35.
61. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17:1362-72.
62. Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-76.
63. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68:2829-36.
64. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70:536-42.
65. Van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-92.
66. Lee MY, Shim MS, Kim BH, et al. Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J 2011;35:130-7.
67. Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009;24:73-84.
68. Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol 1987;10:198-220.
69. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.
Рецензия
Для цитирования:
Гегенава Б.Б., Драпкина О.М. СЕЛЕКТИВНЫЙ АНТАГОНИСТ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ ЭПЛЕРЕНОН В КАРДИОЛОГИЧЕСКОЙ ПРАКТИКЕ. Рациональная Фармакотерапия в Кардиологии. 2015;11(2):177-181. https://doi.org/10.20996/1819-6446-2015-11-2-177-181
For citation:
Gegenava B.B., Drapkina O.M. A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE. Rational Pharmacotherapy in Cardiology. 2015;11(2):177-181. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-2-177-181
Просмотров:
1130
Послать статью по эл. почте 